Articles

TGaS Advisors brought together digital marketing executives at GlaxoSmithKline, Novo Nordisk, Ortho-McNeil Janssen, Sanofi-Aventis, Shire, Takeda, and other companies to develop consensus on key aspects of FDA Guidelines on social media. Their conclusions, together with benchmark information gathered from 62 brands across 18 companies, are being presented at the DDMAC hearings on, Friday, Nov. 13, by Donna Wray, who heads the Internet and Relationship Marketing Practice at TGaS Advisors.

View Presentation

The arms race is over, and it’s time to reinvent pharma sales. Here’s what forward-looking companies are experimenting with—and how it’s working.

Companies are exploring new business opportunities and models to better manage operations located around the world.

Experts anticipate that mobile marketing is going to contribute significantly to the pharmaceutical marketing mix in the future.

TGaS Advisors’ vice president Gary McWalters believes the drug industry must rethink its approach to regulatory compliance and how it works with healthcare professionals.

In these tough times, how does pharma see its future? How confident are top executives in the future of the industry and their own company? Does size make a difference? These were among the questions TGaS Advisors asked 20 operations executives from a cross-section of large, mid-tier, and specialty companies for its annual State of Commercial Operations benchmark conducted late last year.

Posted with permission from HBA.

Jim Mercante, Partner, provides insights on the automation of the promotional review/approval process, closed-loop marketing, and the development of organizational groups focusing on innovation in sales and marketing.

Stephen Gerard, Managing Partner and Founder comments on ways in which industry execs will be digging deeper into the 2008 balance sheet.

Donna Wray, Director, Management Advisor provides insights on the tightening restrictions on physician honoraria.